VIDEO: EYP-1901 shows continued safety for wet AMD treatment

Issue: August 25, 2022

ByDavid W. Mullin

ByNancy S. Lurker

Fact checked byChristine Klimanskis, ELS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — In this Healio Video Perspective from the ASRS meeting, Nancy Lurker, CEO of EyePoint Pharmaceuticals, announces the 12-month results from the DAVIO clinical trial of EYP-1901 for wet age-related macular degeneration.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Lurker reports being the CEO of EyePoint Pharmaceuticals.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment